Genetic Testing of Cerebrospinal Fluid to Diagnose and Monitor Glioblastoma

Evaluating the Role of Cerebrospinal Fluid (CSF) Cell-free DNA (cfDNA) as a Prognostic Biomarker in Glioblastoma

NCT05927610•Memorial Sloan Kettering Cancer Center

Summary

The goal of this study is to determine the utility of cerebrospinal fluid (CSF) cell-free DNA (cfDNA) as a prognostic biomarker in glioblastoma (GBM).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Cohort A
•Participants must be able to understand and be willing to sign a written informed consent document
•Age ≥ 18 years
•MRI with contrast-enhancing lesion concerning for high-grade glioma in absence of known systemic malignancy
•Clinical consensus of presumed diagnosis of high grade glioma between (1) neuroradiology (2) neurosurgery; and (3) principal investigator
•No prior tumor directed therapy
•Planned radiation therapy for glioblastoma
•Patients must be willing and able to tolerate MRI scans and/or CT scans w/ contrast
•Patients must be willing to consent to MSK IRB#12-245
•Cohort B
+8 more criteria

Exclusion Criteria

•Cohorts A and B
•Any case for which there is a medical contraindication or safety concern regarding a lumbar puncture under standard medical guidelines at MSK
•Refusal to undergo serial lumbar punctures

Key Dates

Start Date

June 19, 2023

Primary Completion Date

February 15, 2024

Completion Date

February 15, 2024

Last Updated

May 21, 2025

Conditions

Glioblastoma

Interventions

Lumber Puncture

DIAGNOSTIC_TEST

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

NCT06860594

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant+5 more

View study

RECRUITING

Targeted Pediatric High-Grade Glioma Therapy

NCT05839379

High Grade GliomaDiffuse Intrinsic Pontine Glioma+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 21, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Genetic Testing of Cerebrospinal Fluid to Diagnose and Monitor Glioblastoma

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Targeted Pediatric High-Grade Glioma Therapy

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma